Reporting from the AACR Annual Meeting 2021, Sophie Piperno-Neumann discusses important results from two studies covering advanced melanoma testing in innovative immunotherapy strategies. First she describes practice changing results in metastatic uveal melanoma, comparing the bi-specific protein tebentafusp with the investigator's choice treatment. Then she comments on the promising results obtained at 28 months follow-up of the study in advanced melanoma patients treated with autologous TIL therapy lifileucel.
- CT002 - Phase 3 randomized trial comparing tebentafusp with investigator’s choice in first line metastatic uveal melanoma
- CT008 - Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced (unresectable or metastatic) melanoma: durable duration of response at 28 month follow up.
This video was supported with an educational grant from Roche.
The selection of study results covered in this track is exclusively under the responsibility of ESMO and the speakers selected by ESMO.